MRC2-blocking antibody

An MRC2-blocking antibody is a monoclonal antibody designed to target and inhibit Mannose Receptor C Type 2 (MRC2, also known as uPARAP, Endo180, or CD280). MRC2 is an endocytic collagen receptor involved in extracellular matrix remodeling and is expressed by pro-inflammatory immune cells [1.1]. In the context of neuroinflammatory diseases like multiple sclerosis (MS), MRC2-blocking antibodies inhibit the degradation of collagen IV (Col IV) surrounding the endothelial cells of the blood-brain barrier (BBB), thereby reducing the transendothelial migration and infiltration of pathogenic T lymphocytes into the central nervous system (CNS). Preclinical studies in experimental autoimmune encephalomyelitis (EAE) models have demonstrated that treatment with MRC2-blocking antibodies (such as clones 9b7 and 2h9) significantly attenuates clinical disease severity and limits CNS neuroinflammation.

Other names

anti-Endo180 blocking antibodyanti-Endo-180 blocking antibodyanti-Endo 180 blocking antibodyanti-MRC2 blocking antibodyanti-MRC-2 blocking antibodyanti-MRC 2 blocking antibodyanti-uPARAP blocking antibodyclone 2h9clone2h9clone-2h9clone 9b7clone9b7clone-9b7Endo180-blocking antibodyEndo-180-blocking antibodyEndo 180-blocking antibodyuPARAP-blocking antibody